Results 21 to 30 of about 172,168 (267)

Sphagneticola Trilobata (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL

open access: yesPlants, 2021
We will study the effects of the methanol extract of Sphagneticola trilobata (L.) Pruski (Asteraceae) (MeST) on the growth of leukemia cells that may contain the BCR/ABL gene. This study also clarifies the mechanism of this effect on these cells.
Hoang Thanh Chi   +2 more
doaj   +1 more source

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis

open access: yesCell Death and Disease, 2021
Chronic myelogenous leukemia (CML) is a clonal malignancy of hematopoietic stem cells featured with the fusion protein kinase BCR-ABL. To elicit the mechanism underlying BCR-ABL stability, we perform a screen against a panel of deubiquitinating enzymes ...
Shuoyi Jiang   +9 more
doaj   +1 more source

Molecular Pathways: BCR-ABL [PDF]

open access: yesClinical Cancer Research, 2012
Abstract Aberrant tyrosine kinase activity plays a critical role in many hematologic disorders, including chronic myeloid leukemia characterized by the constitutive activity of BCR-ABL. ABL therefore represents a crucial target for new therapeutic strategies.
CILLONI, Daniela, SAGLIO, Giuseppe
openaire   +3 more sources

The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia. [PDF]

open access: yesPLoS Genetics, 2015
The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia.
Anahita Rafiei   +8 more
doaj   +1 more source

Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

open access: yesFrontiers in Oncology, 2021
The treatment of chronic myeloid leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKIs), such as imatinib, has yielded clinical success. However, the direct targeting of BCR-ABL does not eradicate CML cells expressing mutant BCR-ABL, especially ...
Ke Yang   +10 more
doaj   +1 more source

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway

open access: yesMolecular Therapy: Oncolytics, 2020
Chronic myeloid leukemia (CML) is caused by the Philadelphia (Ph+) chromosome carrying the BCR-ABL oncogene, a constitutively active tyrosine kinase. The discovery of imatinib represents a major success story in the treatment against CML.
Liuya Wei   +13 more
doaj   +1 more source

A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL

open access: yesbioRxiv, 2020
Targeted protein degradation (TPD) and proteolysis-targeting chimeras (PROTACs) have arisen as powerful therapeutic modalities for degrading specific protein targets in a proteasome-dependent manner.
Bingqi Tong   +12 more
semanticscholar   +1 more source

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition

open access: yesFrontiers in Pharmacology, 2023
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation tyrosine kinase inhibitor (TKIs). The T315I mutant form of BCR-ABL is the most
Congying Gao   +6 more
doaj   +1 more source

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib

open access: yesHaematologica, 2010
Background Selective inhibition of the BCR-ABL tyrosine kinase by RNA interference has been demonstrated in leukemic cells. We, therefore, evaluated specific BCR-ABL small interfering RNA silencing in BCR-ABL-positive cell lines, including those ...
Michael Koldehoff   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy